Chronic and complex conditions often require sustained behavioral change for effective self-management of treatment, lifestyle change and wellbeing. Yet, every individual is likely to have a complex mix of barriers to achieving this, such as:
Unhelpful illness and treatment beliefs such as how long their condition will last or a low perceived need for medication
Low health literacy limiting their understanding of instructions and advice
Negative emotions affecting their motivation to engage in helpful behaviors
Practical challenges with building and sticking to new treatment or health routines
Self-management challenges can impact medication-taking—for example: adjusting, skipping or even stopping despite medical advice. This in turn can impact overall health outcomes—but the good news is people can be empowered to overcome their modifiable barriers with the right support.
Systematic reviews of patient support programs in the US and Europe, including those sponsored by pharmaceutical companies to complement the healthcare team's role, indicate that they can deliver better outcomes, including improved adherence, quality of life, clinical and economic outcomes.1,2,3
The preponderance of evidence suggests a positive impact of PSPs on adherence, clinical and humanistic outcomes. Although less often measured, health care utilization and costs are also reduced following PSP implementation.1
At Atlantis Health, we’ve demonstrated that effective solutions grounded in behavioral science, co-designed and personalized to support long-term self-management drive improved outcomes across a range of therapy areas and treatments.4,5,6 This includes positve patient experience, with our average participant satisfaction ratings of 88% and average Net Promoter Score of 74.
Driving positive outcomes for patients, healthcare professionals and pharmaceutical clients requires more than just providing information.
Our approach to designing illness empowerment solutions is anchored in robust behavioral frameworks, data and insights to identify the relevant and modifiable factors influencing adherence and other health behaviors.7
This includes unhelpful medication and illness beliefs that a person may hold that can be addressed with targeted interventional support.
We define a comprehensive strategy as the foundation for developing tailored behavioral interventions that empower self-management success.
We incorporate the lived experience of people managing long-term conditions, as well as caregivers and healthcare professionals (HCPs).
Understanding their challenges and perspectives, we collaborate with various stakeholders to design omnichannel experiences that deliver support, resources and services that are engaging, health-literate, culturally sensitive and empathetic—and personalized to each person’s beliefs and behavioral support needs.
How does every individual receive a highly personalized support experience that complements the care of a health provider?
Leveraging AI capabilities, data analytics and advances in behavioral science further enhances engagement, empowerment and health outcomes.
Our secure, configurable technology platforms enable individual assessments and data collection to deliver an ongoing journey of targeted interventional support to empower behavior change over time and at scale—as well as measure engagement, adherence, other health behaviors and participant satisfaction to demonstrate impact and value.
AI-powered experiences can deliver cost-effective scaling but also flag when human intervention is the best next action, ensuring ethical, accurate and compliant use of these new technologies—a key focus of our roadmap.
97% persistence at 6 months: Omnichannel Support for People Living With Narcolepsy
20% annual increase in filled prescriptions: myMeds—A multichannel support program for Type 2 Diabetes
38% increase in persistence: Supporting Neovascular Age-Related Macular Degeneration (nAMD) patients to continue treatment
References
1. Ganguli A, Clewell J, Shillington AC. The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review. Patient Prefer Adherence. 2016 Apr 28;10:711-25. https://doi.org/10.2147/ppa.s101175 PMID: 27175071; PMCID: PMC4854257
2. Sacristán, J.A., Artime, E., Díaz-Cerezo, S. et al.The Impact of Patient Support Programs in Europe: A Systematic Literature Review. Patient 15, 641–654 (2022). https://doi.org/10.1007/s40271-022-00582-y
3. Rabe APJ, Loke WJ, Kielar D, Morris T, Shih VH, Olinger L, Musat MG, Lan Z, Harricharan S, Fulton O, Majeed A, Heaney LG. Impact of patient support programmes among patients with severe asthma treated with biological therapies: a systematic literature review and indirect treatment comparison. BMJ Open Respir Res. 2024 May 2;11(1):e001799.
https://doi.org/10.1136/bmjresp-2023-001799 PMID: 38697674; PMCID: PMC11086199.
4. Alcazar, B., de Lucas, P., Soriano, J.B. et al.The evaluation of a remote support program on quality of life and evolution of disease in COPD patients with frequent exacerbations. BMC Pulm Med 16, 140 (2016). https://doi.org/10.1186/s12890-016-0304-3
5. Koledova Ekaterina, Su Pen-Hua, Chen Yen-Ju, Assefi Aria, Debicki Matias, Cooke Debbie, Jheeta Amrit, Jones Alexander B., Moon Jung Eun. The TUITEK® patient support program improved caregiver-related behaviors on growth hormone treatment adherence. Frontiers in Endocrinology 16 (2025). https://doi.org/10.3389/fendo.2025.1548558
6. Van den Bosch F, Ostor AJK, Wassenberg S, Chen N, Wang C, Garg V, Kalabic J. Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study. Rheumatol Ther. 2017 Jun;4(1):85-96. https://doi.org/10.1007/s40744-017-0061-7
7. Sheils E, Tillett W, James D, Brown S, Dack C, Family H, Chapman SCE. Changing medication-related beliefs: A systematic review and meta-analysis of randomized controlled trials. Health Psychol. 2024 Mar;43(3):155-170. https://doi.org/10.1037/hea0001316